Caricamento...
Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions
Erlotinib—an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)—has commonly been used as a therapeutic option in metastatic non-small-cell lung cancer (nsclc) patients in the second- or third-line treatment setting. A mutation in the EGFR gene (EGFR M+) confers an i...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Multimed Inc.
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3267591/ https://ncbi.nlm.nih.gov/pubmed/22328842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.949 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|